

Millions of dots: violet makes your plot more interesting
New eBioscience™ Super Bright antibody conjugates

[Learn more](#)

invitrogen
by Thermo Fisher Scientific



This information is current as of July 25, 2017.

Aim2 Deficiency in Mice Suppresses the Expression of the Inhibitory Fc γ RIIB) through the Induction of the IFN-Inducible p202, a Lupus Susceptibility Protein

Ravichandran Panchanathan, Hui Shen, Xin Duan, Vijay A. K. Rathinam, Loren D. Erickson, Katherine A. Fitzgerald and Divaker Choubey

J Immunol 2011; 186:6762-6770; Prepublished online 6 May 2011;

doi: 10.4049/jimmunol.1003638

<http://www.jimmunol.org/content/186/12/6762>

References This article **cites 54 articles**, 19 of which you can access for free at:
<http://www.jimmunol.org/content/186/12/6762.full#ref-list-1>

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2011 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Aim2 Deficiency in Mice Suppresses the Expression of the Inhibitory Fc γ RIIB through the Induction of the IFN-Inducible p202, a Lupus Susceptibility Protein

Ravichandran Panchanathan,^{*,†} Hui Shen,^{*,†} Xin Duan,^{*} Vijay A. K. Rathinam,[‡] Loren D. Erickson,[§] Katherine A. Fitzgerald,[‡] and Divaker Choubey^{*,†}

Murine *Aim2* and *Ifi202* genes (encoding for the Aim2 and p202 proteins) are members of the IFN-inducible *Ifi200* gene family. The *Aim2* deficiency in mice activates IFN signaling and stimulates the expression of the lupus susceptibility gene, the *Ifi202*, located within the NZB autoimmunity 2 (*Nba2*) interval. Given that the deficiency in the expression of the *Fcgr2b* gene (encoding for the inhibitory Fc γ RIIB receptor) is associated with increased lupus susceptibility in mice, we investigated whether the Aim2 protein could regulate the expression of *Fcgr2b* gene. In this article, we report that *Aim2* deficiency in mice suppresses the expression of the Fc γ RIIB receptor. Interestingly, the *Fcgr2b*-deficient cells expressed increased levels of the IFN- β , activated IFN signaling, and expressed reduced levels of the Aim2 protein. Treatment of splenic cells with IFN- α or - γ reduced levels of the Fc γ RIIB mRNA and protein and also decreased the activity of the Fc γ RIIB p(-729/+585) Luc reporter. Moreover, levels of the Fc γ RIIB receptor were significantly higher in the *Stat1*-deficient splenic cells than in the wild-type cells. Accordingly, increased expression of IFN- β in lupus-prone B6.*Nba2*-ABC mice, as compared with non-lupus-prone C57BL/6 (B6) or B6.*Nba2*-C mice, was associated with reduced expression of the Fc γ RIIB receptor. Notably, overexpression of the p202 protein in cells decreased the expression of the *Aim2* gene, activated the IFN response, and suppressed the expression of the *Fcgr2b* gene. These observations demonstrate that the expression of Aim2 protein is required to maintain the expression of the *Fcgr2b* gene and also predict epistatic interactions between the *Ifi200* genes and the *Fcgr2b* gene within the *Nba2* interval. *The Journal of Immunology*, 2011, 186: 6762–6770.

Several chromosomal loci appear to contribute to the development of systemic lupus erythematosus (SLE), an autoimmune disease with strong gender bias in humans and in mouse models of the disease (1–6). In particular, the NZB autoimmunity 2 (*Nba2*) locus (~90–97 cM; locus), which is located on the distal portion of the NZB chromosome 1, has been shown to be a major genetic contribution to the disease susceptibility in the (NZB \times NZW)_{F1} mice (7, 8). The generation of the B6.*Nba2* congenic (congenic for the *Nba2* interval on the C57BL/6 [B6] genetic background) mice identified the IFN-inducible *Ifi202* gene (encoding for the p202 protein), a member of the *Ifi200* gene family, as a candidate lupus susceptibility gene within the *Nba2* interval (8). Increased levels of the p202 protein are

associated with defects in apoptosis of the B6.*Nba2* splenic B cells upon ligation with anti-IgM in vitro. Moreover, the female mice at the age of ~7 mo produce pathogenic anti-nuclear Abs and splenomegaly. Interestingly, these congenic female mice do not develop a kidney disease (8), indicating interactions of the *Nba2* locus with other loci for the development of the kidney disease.

On the basis of the sequence polymorphisms that are identified in the *Nba2* interval genes, it has been proposed that the interval may contain several candidate lupus susceptibility genes (8–12). The candidate genes include the *Slam* family genes (12), the *Fcgr2b* gene (encoding for the inhibitory Fc γ RIIB receptor) (10), and the IFN-inducible *Ifi202* gene (8). Generation of B6.*Nba2* subcongenic lines (B6.*Nba2*-A, B6.*Nba2*-B, and B6.*Nba2*-C) revealed that the subinterval A (comprising the *Fcgr2b* gene) and the subinterval B (comprising the *Slam* family genes) cooperate with each other to influence the autoantibody production (13). Moreover, the study revealed that genes within the subinterval C (comprising the *Ifi200* family genes) may negatively regulate the expression of the *Fcgr2b* gene and inhibit the Fc γ RIIB-induced apoptosis (13).

IFNs, a family of cytokines, exert multiple biological effects on the immune system by regulating the differentiation, proliferation, and survival of immune cells (14, 15). Importantly, the biological activities of IFNs are mediated by the IFN-inducible proteins (16). The IFN family includes type I (IFN- α and IFN- β) and type II (IFN- γ) IFNs (14, 15). Both types of IFNs have been investigated for their role in SLE disease (15). Notably, increased levels of IFN- α have been detected in the sera of SLE patients (15, 17). Moreover, activation of IFN-stimulated genes (ISGs) in PBMCs of lupus patients is correlated with severity of the disease (17). Accordingly, mice that are deficient in the type I IFNR (and do not

*Department of Environmental Health, University of Cincinnati, Cincinnati, OH 45267; †Department of Veterans Affairs, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH 45220; ‡Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655; and §Department of Microbiology, University of Virginia, Charlottesville, VA 22908

Received for publication November 3, 2010. Accepted for publication April 14, 2011.

This work was supported by National Institutes of Health Grant AI066261 (to D.C.). A grant from the Lupus Research Institute supported work in the laboratory of L.D.E. V.A.K.R. is supported by a postdoctoral fellowship from the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant AI057159). K.A.F. is supported by National Institutes of Health Grant AI083713.

Address correspondence and reprint requests to Dr. Divaker Choubey, Department of Environmental Health, University of Cincinnati, 3223 Eden Avenue, P.O. Box 670056, Cincinnati, OH 45267. E-mail address: Divaker.choubey@uc.edu

Abbreviations used in this article: B6, C57BL/6; BMDM, bone marrow-derived macrophage; DC, dendritic cell; ISG, IFN-stimulated gene; *Nba2*, NZB autoimmunity 2; SLE, systemic lupus erythematosus.

Copyright © 2011 by The American Association of Immunologists, Inc. 0022-1767/11/\$16.00

express increased levels of ISGs) do not develop the disease (18, 19). These studies indicate a role for ISGs (and the corresponding effector proteins) in the development of SLE.

One family of the ISGs is the *Irf200* gene family, which encodes for structurally related proteins (the p200-family proteins) (20–22). The family includes the murine (e.g., *Irf202a*, *Irf202b*, *Irf203*, *Irf204*, and *Aim2*) and human (e.g., *MNDA*, *IFIX*, *IFI16*, and *AIM2*) genes (22). Most p200 family proteins (except the human AIM2 and murine Aim2 proteins) are detected in the cytoplasmic as well as in the nuclear fractions, and the IFN treatment of certain cell types potentiates the nuclear localization of the p202 protein (23). Interestingly, recent studies revealed that p202 (24), p204 (25), Aim2 (26), IFI16 (25), and AIM2 (27, 28) proteins can sense cytosolic dsDNA and initiate an innate immune response. Both Aim2 and AIM2 proteins, upon sensing dsDNA, form an inflammasome (29, 30), which through the activation of caspase-1, increases the secretion of proinflammatory cytokines, including IL-1 β and IL-18, and induces cell death by pyroptosis (caspase-1–dependent death) in macrophages. In contrast to the Aim2/AIM2 proteins, upon sensing dsDNA, the p204 and IFI16 proteins recruit a stimulator of IFN genes protein to stimulate the expression of IFN- β through the activation of IFN-regulated factor 3 and NF- κ B (25).

FcRs for IgG are key players in the regulation of innate and adaptive immune responses (31–33). In mice, there are four Fc γ Rs. Upon stimulation, the Fc γ RI and Fc γ RIII transduce the stimulatory signals through FcR γ -chain–associated intracellular ITAM. In contrast, the Fc γ RIIB receptor transduces inhibitory signals via intracellular ITIMs. The Fc γ RIIB is the only Fc γ R, which is expressed by B cells (32, 33). Therefore, stringent control of its expression is critical in determining its effects on the immune system. Several isoforms of the inhibitory Fc γ RIIB receptor have been reported in humans and mice (32, 33). The Fc γ RIIB1 isoform, which is a membrane protein, is predominantly expressed by B cells. The Fc γ RIIB2 isoform (a membrane protein) is predominantly expressed by myeloid-derived cells. Both B1 and B2 isoforms are encoded by the same gene through alternative splicing of mRNA (33). When expressed by immune cells, the Fc γ RIIB receptor inhibits the functions of the activating Fc γ Rs such as phagocytosis and proinflammatory cytokine release (31–33). Therefore, Fc γ RIIB receptor regulates many different aspects of immune and inflammatory responses. Consistent with the immunoregulatory role of the Fc γ RIIB receptor, mice that are deficient in the Fc γ RIIB receptor expression develop SLE disease spontaneously on certain genetic backgrounds (34–36). Interestingly, the selective blockade of the inhibitory Fc γ RIIB receptor in human dendritic cells (DCs) and monocytes induces a type I IFN response (37). The induction of the type I IFN response results in activation of STAT1 (by phosphorylation on Tyr⁷⁰¹) and increased steady-state levels of mRNAs that encode for the IFN-inducible proteins, including the AIM2 and IFI16 proteins (37). Although polymorphisms involving short deletions in the promoter and intronic regions of the *Fcgr2b* gene are associated with reduced steady-state levels of mRNA in certain lupus-prone strains of mice (including the NZB mice) (10, 38, 39), the molecular mechanisms that regulate the expression of the *Fcgr2b* gene remain unknown.

Generation of *Aim2*-deficient mice revealed that the Aim2 protein is not needed for IFN- β production after certain bacterial or viral infections (26, 40, 41). Upon infections with certain intracellular pathogens, immune cells (splenic cells and bone marrow-derived macrophages [BMDMs]) from the *Aim2*-deficient mice are defective in the activation of caspase-1, secretion of IL-1 β and IL-18, and induction of cell death *in vitro* (26). Notably,

the *Aim2* deficiency in mice increases the IFN- β expression, stimulates the expression of the *Irf202* gene, and potentiates the nuclear localization of the p202 protein (42). Given that the p200 family proteins are predicted to negatively regulate the expression of the *Fcgr2b* gene (13), we investigated whether the Aim2 deficiency could regulate the expression of the inhibitory Fc γ RIIB receptor. In this article, we report that the expression of Aim2 protein is required to maintain the expression of the inhibitory Fc γ RIIB receptor.

Materials and Methods

Mice

We have described the generation of the *Aim2*-deficient mice (26). These mice are on the mixed (129 \times B6) genetic background. Wild-type and *Aim2*-deficient mice were housed in specific pathogen-free animal facilities at the University of Massachusetts Medical School (Worcester, MA). The B6-*Nba2*-ABC (same as B6*Nba2*) (13), B6.*Nba2*-C (13), and B6 mice were housed in pathogen-free animal facilities at the University of Virginia (Charlottesville, VA). The *Fcgr2b*-deficient (mice on the B6 genetic background) and *Stat1*-deficient (mice on the 129S6 genetic background) mice and the corresponding wild-type mice were purchased from Taconic Farms (Germantown, NY). B6 and NZB male and female mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were housed in pathogen-free animal facilities at the University of Cincinnati (Cincinnati, OH). The Institutional Animal Care and Use Committee at the institution, where the mice were housed, approved the protocol to use mice for studies described in this article.

Splenocytes isolation, cell culture, and treatments

Total splenocytes that were prepared from age and strain-matched male or female mice were resuspended in RPMI 1640 medium supplemented with 10% FBS. When indicated, splenic B cells (B220⁺) were purified using magnetic beads (purification kit purchased from Miltenyi Biotec), allowing the positive selection of the cells (43). The purified (90–95% pure) B cells were used immediately for additional experiments. Unless otherwise indicated, splenic cells from two or more mice were pooled to prepare total RNA or protein extracts.

Murine macrophage RAW264.7 and J774.A1 cell lines (purchased from the American Type Culture Collection) were maintained as suggested by the supplier. When indicated, subconfluent cultures of the murine macrophage cell lines were either left without any treatment or treated with the universal IFN- α (1000 U/ml; from PBL Biomedical laboratories, Piscataway, NJ) or murine IFN- γ (10 ng/ml; from R&D Systems, Minneapolis, MN) for the time period indicated.

To ectopically overexpress the p202 protein in RAW264.7 cells, cells in a 6-well plate were transfected with an empty vector (pCMV) or p202 expression plasmid (pCMV-202b) using the FuGene 6 transfection reagent (Roche Applied Science, Indianapolis, IN) as described previously (43). Twenty-four hours after transfections, cells were split, and the transfected cells were selected in G418 (400 μ g/ml) for ~10–15 d. Colonies that exhibited G418 resistant were pooled. For experiments, cell cultures were maintained without G418 in the medium for several days.

To knockdown the expression of the *Aim2* or *Irf202* gene in J774.A1 cells, cells in a 6-well plate were infected with lentivirus (purchased from Santa Cruz Biotechnology, Santa Cruz, CA) encoding either short hairpin RNA to *Aim2* (sc-140968-V) or *Irf202* (sc-40698-V) gene. As a control, cells were infected with the lentivirus encoding a control short hairpin RNA (sc-108080). Twenty-four hours postinfections, cells were selected in puromycin (1 μ g/ml) for 1 wk. Cells that exhibited puromycin resistance were pooled. For experiments, cell cultures were maintained without puromycin in the medium for several days.

Reporter assays

Reporter assays were performed essentially as described previously (43). In brief, subconfluent cultures of RAW264.7 cells (in a 6-well plate) were transfected with the reporter plasmid Fc γ RIIB p(–729/+585) Luc (2.5 μ g; the plasmid provided by Dr. J.E. Gessner, Hannover Medical School) (44) and pRL-TK (0.5 μ g; purchased from Promega, Madison, WI), using FuGENE 6 (Roche Applied Science), as suggested by the supplier. The transfected cells were either left untreated (control) or treated with the murine IFN- γ (10 ng/ml for 14 h). Cells were harvested between 40 and 45 h after transfections, and the firefly and *Renilla* dual luciferase activities were determined as described previously (43).

Isolation of RNA from splenocytes and RT-PCR

Splenocytes ($5\text{--}8 \times 10^6$ cells) were used to prepare total RNA using the TRIzol (Invitrogen, Carlsbad, CA) method (43), and 0.5–2 μg RNA was used for RT-PCR using the Superscript one-step RT-PCR system (from Invitrogen). Semiquantitative PCR was performed using a pair of primers specific to the *Ifi202* (primers, forward: 5'-ggctacttaccactcagaat-3' and reverse: 5'-ctctagatgccaactgctgttg-3'), *Aim2* (primers, forward: 5'-acagtggccacggaga-3' and reverse: 5'-agtgactctactccaca-3'), *Fcgr2b* (primers, forward: 5'-aagcttaggaaggacactgc-3' and reverse: 5'-atcctggccttctggcttc-3'), or the murine *Ifnb* (primers, forward: 5'-ctcgtctctgctgtctctcca-3' and reverse: 5'-tctcgtctatccatagggate-3') gene. The conditions for the regular PCR were the same as described previously (43).

To perform quantitative real-time TaqMan PCRs, we used the 7300 Real-Time PCR System (from Applied Biosystems, Foster City, CA) and the commercially available real-time TaqMan gene expression assays. The PCR cycling program has been described previously (43). The TaqMan assays for *Ifi202* (Assay Id number Mm0304 8198_m1; the assay allows for the detection of both the *Ifi202a* and *Ifi202b* mRNA levels), *Aim2* (Assay Id number Mm01295719_m1), *Ifnb* (Assay Id number Mm00439552_s1), *Fcgr2b* (Assay Id number Mm00438875_m1; the assay allows for the detection of mRNA encoding both the B1 and B2 isoforms of the FcγRIIB receptor), *2,5AS* (Assay Id number Mm00836412_m1), *Mx1* (Assay Id number Mm00487796_m1), *Rsad2* (Assay Id number Mm00491265_m1), the endogenous *Actb* control (catalog number 4352933E), and β_2 -microglobulin (Assay Id number Mm00437762_m1) were purchased from the Applied Biosystems and used as suggested by the supplier.

Immunoblotting

Total cell lysates containing approximately equal amounts of proteins prepared from splenocytes or murine macrophage cell lines were subjected to immunoblotting as described previously (43). The p202 antiserum, which allows the detection of both p202a and p202b proteins in immunoblotting, has been described previously (43). When indicated, we also used mAbs to p202 (sc-166253) from Santa Cruz Biotechnology to detect the p202 protein in extracts from the murine cell lines. Polyclonal Abs that were raised against murine Aim2 protein have been described previously (42). Abs to detect the murine FcγRIIB receptor (sc-28842) in immunoblotting were purchased from Santa Cruz Biotechnology. Abs to STAT1 (number 9172), p-STAT1^{Tyr-701} (number 9171), and β -actin (number 4967) were purchased from Cell Signaling Technology (Danvers, MA).

Statistical analyses

The statistical significance of differences in the measured mean frequencies between the two groups of observations was calculated using the Student two-tailed *t* test. A *p* value <0.05 was considered significant.

Results

Aim2 deficiency or knockdown decreases the expression of the *Fcgr2b* gene

Aim2 deficiency in splenic and bone marrow-derived cells increases the constitutive expression of type I IFN (IFN- β) and certain IFN-inducible proteins, including the p202 protein, in a gender-dependent manner (42). Given that the *Ifi200* family genes that are located within the C region of the *Nba2* interval may negatively regulate the FcγRIIB receptor expression (13), we investigated whether the lack of *Aim2* expression in the *Aim2*-knockout mice (26) could regulate the expression of the FcγRIIB receptor. As shown in Fig. 1, *Aim2*-deficient B cells had significantly lower basal levels of the FcγRIIB receptor mRNA (Fig. 1A, 1B) and protein (Fig. 1C) as compared with cells isolated from age- and gender-matched wild-type mice. Interestingly, the FcγRIIB receptor protein levels were measurably higher in the splenic B cells from males than the age-matched females (Fig. 1C). Moreover, the knockdown of *Aim2* expression in the murine macrophage J774.A1 cell line also reduced steady-state levels of FcγRIIB receptor mRNA (Fig. 1D) and protein (Fig. 1E). Collectively, these observations revealed that the *Aim2* deficiency reduces the expression levels of the inhibitory receptor FcγRIIB.




FIGURE 1. *Aim2* deficiency or knockdown decreases the *Fcgr2b* expression. **A**, Total RNA was extracted from the purified splenic B cells that were isolated from wild-type and age-matched *Aim2*-deficient male or female mice (age, 6–8 wk). Steady-state levels of *Fcgr2b* mRNA were analyzed by quantitative TaqMan real-time PCR. The ratio of the test gene to β_2 -microglobulin mRNA was calculated in units (one unit being the ratio of the test gene to β_2 -microglobulin mRNA). Results are mean values of triplicate experiments, and error bars represent SD (***p* < 0.005). **B**, Total RNA as described in **A** was also analyzed by semiquantitative PCR using a pair of primers specific to the indicated genes. **C**, Total cell lysates from purified splenic B cells that were prepared from wild-type (lanes 1, 3) and age-matched *Aim2*-deficient (lanes 2, 4) male or female mice (age, 6–8 wk) were analyzed by immunoblotting using Abs specific to the indicated proteins. The fold change (FC) in the levels of the FcγRIIB receptor protein after normalization with actin protein levels is also indicated. **D**, Total RNA was extracted from stably infected with control lentivirus (C) or sh*Aim2* lentivirus (*Aim2*) J774.A1 cells. The RNA was analyzed by semiquantitative PCR using a pair of primers specific to the indicated gene. **E**, Total cell lysates prepared from J774.A1 cells described in **D** were subjected to immunoblotting to detect the indicated proteins.

Fcgr2b gene deficiency induces a type I IFN response

A selective blockade of the inhibitory FcγRIIB receptor in human DCs and monocytes induces a type I IFN response that results in the activating phosphorylation of STAT1 and increased steady-state levels of mRNAs that code for the IFN-inducible proteins (37). However, it remains unknown whether a similar response is generated in the murine cells that are deficient in the FcγRIIB receptor. Given that the *Aim2* deficiency significantly decreased the expression of FcγRIIB in splenic cells (Fig. 1), we investigated whether the *Fcgr2b* deficiency could induce a type I IFN response. As shown in Fig. 2, the deficiency of the *Fcgr2b* gene in splenic cells (Fig. 2A, 2B), which was associated with reduced steady-state levels of the Aim2 protein (Fig. 2B) and mRNA (Fig. 2C), increased basal levels of IFN- β mRNA (Fig. 2D). Accordingly, we detected higher basal levels of the activated STAT1 (phosphorylated on Tyr⁷⁰¹) and STAT1 proteins in FcγRIIB null than the age- and gender-matched wild-type cells (Fig. 2E; a very long exposure showed bands in lanes 1, 3). Furthermore, consistent with the activation of STAT1 in the *Fcgr2b*-deficient cells, we also noted increased steady-state levels of mRNAs encoded by known IFN-inducible genes, including the *2,5AS* (encoding for 2'-5' oligoadenylate synthetase) *Mx1*, *Rsad2* (encoding for the viperin protein), and *Ifi202*, than the wild-type cells (Fig. 3). These observations demonstrated that the FcγRIIB receptor deficiency in murine splenic cells induces a type I IFN response, which results in the activation of STAT1 and the induction of the IFN-inducible genes.




FIGURE 2. *Fcgr2b* deficiency induces a type I IFN response. *A*, Total RNA was extracted from splenocytes isolated from wild-type (lanes 1, 3) and age-matched *Fcgr2b*-deficient (lanes 2, 4) male or female mice (age, ~8 wk). The RNA was analyzed by semiquantitative PCR using a pair of primers specific to the indicated genes. *B*, Total protein extracts were prepared from splenocytes isolated from wild-type (lanes 1, 3) and age-matched *Fcgr2b*-deficient (lanes 2, 4) male or female mice (age, ~8 wk). Extracts containing approximately equal amounts of proteins were analyzed by immunoblotting for the indicated proteins. *C*, The RNA samples described in *A* were subjected to quantitative real-time PCR to detect levels of the *Aim2* mRNA. The ratio of the *Aim2* mRNA to the β_2 -microglobulin mRNA was calculated in units (one unit being the ratio of the test gene to β_2 -microglobulin mRNA). The relative steady-state levels of *Aim2* mRNA in male mice are indicated as 1.0. Results are mean values of triplicate experiments, and error bars represent SD. *D*, The RNA samples described in *A* were subjected to quantitative real-time PCR to detect levels of the *Ifnb* mRNA. The ratio of the *Ifnb* mRNA to the β_2 -microglobulin mRNA was calculated in units (one unit being the ratio of the test gene to β_2 -microglobulin mRNA). The relative steady-state levels of *Ifnb* mRNA in male mice are indicated as 1. Results are mean values of triplicate experiments, and error bars represent SD. *E*, Total protein extracts described in *B* were analyzed by immunoblotting for the indicated proteins. **p* < 0.05, ***p* < 0.01.

Activation of IFN signaling decreases FcγRIIB receptor expression

Given that the *Aim2* deficiency induces a type I IFN response (42) and also decreases steady-state levels of FcγRIIB mRNA and protein (Fig. 1), we explored whether the activation of IFN-signaling could negatively regulate the expression of the *Fcgr2b*

gene. As shown in Fig. 4, treatment of B6 splenic cells with IFN- α or IFN- γ (we also used IFN- γ because it suppresses the transcription from the *Fcgr2b* gene promoter; Ref. 44) significantly (>50%) reduced steady-state levels of FcγRIIB mRNA (Fig. 4A) and protein (Fig. 4B). However, levels of the FcγRI mRNA did not decrease (data not shown). Interestingly, the decrease in FcγRIIB protein levels was time dependent and more appreciable after 48 h of the treatment with IFN- α . This decrease in the FcγRIIB receptor protein levels after a prolonged treatment with IFN- α is consistent with a long predicted $t_{1/2}$ (>30 h) of the protein. Moreover, as expected (44), the treatment of RAW264.7 cells with IFN- γ significantly decreased the activity of the FcγRIIB p(-729/+585)-Luc reporter gene, the expression of which was driven by the 5'-regulatory region (-729 to +585 bp) of the murine *Fcgr2b* gene (Fig. 4C) (44). The above observations that the activation of the IFN signaling in splenic cells reduced the expression of *Fcgr2b* gene prompted us to compare steady-state levels of FcγRIIB mRNA and protein between the *Stat1*-deficient and wild-type cells. Expectedly, levels of the FcγRIIB mRNA (Fig. 4D; these cells express detectable levels of mRNA encoding for the B1 and B2 isoforms of the FcγRIIB receptor) and protein (Fig. 4E) were significantly higher in splenic cells from *Stat1*-deficient than the age- and gender-matched wild-type mice. In summary, these observations demonstrate that the activation of IFN signaling in immune cells, which resulted in the activating phosphorylation of the STAT1, negatively regulates the expression of the inhibitory FcγRIIB receptor.




FIGURE 3. *Fcgr2b* deficiency induces the expression of IFN-inducible genes. Total RNA was isolated from total splenocytes isolated from wild-type and age-matched *Fcgr2b*-deficient male or female mice (age, ~8 wk). Steady-state levels of mRNA corresponding to the IFN-inducible 2,5 AS (*A*), *Mx1* (*B*), *Rsad2* (*C*), and *Ifi202* (*D*) genes were analyzed by quantitative TaqMan real-time PCR. The ratio of the test gene to β_2 -microglobulin mRNA was calculated in units (one unit being the ratio of the test gene to β_2 -microglobulin mRNA). Results are mean values of triplicate experiments, and error bars represent SD. **p* < 0.05, ***p* < 0.005, ****p* < 0.0005.

Increased expression of IFN-β in lupus-susceptible mice is associated with reduced expression of the FcγRIIB receptor

Lupus-susceptible preautoimmune (age, ~9 wk) NZB and B6.*Nba2-ABC* (same as B6.*Nba2*) female mice express lower levels of the *Aim2* mRNA as compared with age-matched B6 females (42). Therefore, our above observations that the *Aim2* deficiency is associated with reduced levels of FcγRIIB mRNA and protein (Fig. 1) prompted us to compare the expression of FcγRIIB between non-lupus-prone and lupus-prone mice. As shown in Fig. 5, basal steady-




FIGURE 4. Activation of IFN-signaling decreases Fc γ RIIB receptor expression. *A*, Splenocytes isolated from the B6 female mice (age ~10 wk) were either left without any treatment or treated with IFN- α (1000 U/ml) or IFN- γ (10 ng/ml) for 18 h. Total RNA was extracted after the treatment and analyzed by quantitative real-time PCR for Fc γ RIIB mRNA levels. The ratio of the Fc γ RIIB mRNA to the β_2 -microglobulin mRNA was calculated in units (one unit being the ratio of the test gene to β_2 -microglobulin mRNA). The relative steady-state levels of Fc γ RIIB mRNA in untreated control cells are indicated as 1.0. Results are mean values of triplicate experiments, and error bars represent SD. *B*, Splenocytes isolated from the B6 female mice (age ~10 wk) were either left without any treatment or treated with IFN- α (1000 U/ml) for the indicated time (h). Total cell extracts were subjected to immunoblotting using specific Abs to the indicated proteins. *C*, Cultures of RAW264.7 cells in a 6-well plate were transfected with the Fc γ RIIB p(-729/+585) Luciferase reporter plasmid (2.5 μ g) along with pRL-TK (0.5 μ g) reporter plasmid using FuGENE 6 transfection reagent. Twenty-four hours after transfections, cells were either left untreated or treated with IFN- γ . Forty to 45 h after transfections, cells were processed for the dual luciferase activity. Results are mean values of triplicate experiments, and error bars represent SD. *D*, Total RNA was prepared from splenocytes isolated from wild-type (lanes 1, 3) and age-matched *Stat1*-deficient (lanes 2, 4) male or female mice (age ~9 wk). The RNA was analyzed by semiquantitative PCR using a pair of primers specific to the indicated genes. *E*, Protein extracts containing equal amounts of proteins that were prepared from wild-type (lanes 1, 3) and age-matched *Stat1*-deficient (lanes 2, 4) male or female mice (age ~9 wk) were subjected to immunoblotting to analyze the levels of the indicated proteins. FC, fold change in the Fc γ RIIB receptor levels. * p < 0.05.

state levels of Fc γ RIIB mRNA (Fig. 5*A*) and protein (Fig. 5*B*) were measurably lower in the splenic cells from the NZB and B6.*Nba2-ABC* female mice as compared with the age-matched B6 females.

Notably, levels of the Fc γ RIIB receptor were appreciably (~50%) lower in the B6.*Nba2* females than in the age-matched NZB females (Fig. 5*B*, compare lane 3 with lane 2).




FIGURE 5. Increased expression of IFN- β in lupus-susceptible mice is associated with reduced expression of Fc γ RIIB receptor. *A*, Total RNA isolated from splenocytes prepared from age-matched (~9 wk) B6, NZB, or B6.*Nab2* (ABC) female mice was analyzed by quantitative real-time PCR for Fc γ RIIB receptor mRNA levels. The ratio of the Fc γ RIIB mRNA to the β_2 -microglobulin mRNA was calculated in units (one unit being the ratio of the test gene to β_2 -microglobulin mRNA). The relative steady-state levels of Fc γ RIIB mRNA in the B6 female mice are indicated as 1.0. Results are mean values of triplicate experiments, and error bars represent SD. *B*, Total protein extracts from purified B cells (B220⁺) were subjected to immunoblotting for the indicated protein using the specific Abs. *C*, Total RNA extracted from age-matched (~4 mo old) female B6, B6.*Nba2*-C (C), or B6.*Nba2*-ABC (ABC) splenic cells was analyzed by semiquantitative PCR for *Ifnb* mRNA levels. *D*, Total RNA in C was analyzed by quantitative TaqMan real-time PCR using the specific to *Fcgr2b*. The ratio of the *Fcgr2b* mRNA levels to β_2 -microglobulin mRNA levels was calculated in units (one unit being the ratio of the test gene to β_2 -microglobulin mRNA in splenocytes). The relative levels of *Fcgr2b* mRNA levels in the B6 females are indicated as 1.0. Results are mean values of triplicate experiments and error bars represent SD. *E*, Total RNA in C was also analyzed by semiquantitative PCR for *Fcgr2b* mRNA levels. *F*, Total cell extracts from splenocytes prepared from age-matched (~10 wk) B6, NZB, or B6.*Nab2* (ABC) female mice were analyzed by immunoblotting using Abs specific to the indicated proteins. * p < 0.05. FC, fold change in the Fc γ RIIB receptor levels.

Earlier, we noted that reduced expression of the Aim2 protein in preautoimmune (age, ~4 mo old) B6.*Nba2-ABC* female mice is associated with increased expression of IFN- β and p202 protein as compared with age-matched B6 mice (42). Therefore, we compared steady-state levels of IFN- β mRNA in female mice (B6, B6.*Nba2-C*, and B6.*Nba2-ABC*), which differ with respect to the expression of Aim2 and p202 proteins (42). As shown in Fig. 5C, consistent with our previous observations (42), steady-state levels of IFN- β mRNA were readily detectable in the B6.*Nba2-ABC* female mice. However, the levels were either much lower in the B6.*Nba2-C* female mice or not detectable in the B6 females. Importantly, the steady-state levels of Fc γ RIIB mRNA were significantly lower in the B6.*Nba2-ABC* mice as compared with age-matched B6 females (Fig. 5D, 5E). Notably, the difference in the mRNA levels was minimal between the B6 and B6.*Nba2-C* mice. Accordingly, levels of the Fc γ RIIB receptor were ~70% lower in the B6.*Nba2-ABC* cells than the age-matched B6 mice (Fig. 5F). Collectively, the above observations indicated that increased levels of type I IFNs in the lupus-prone female mice are associated with decreased expression of the inhibitory Fc γ RIIB receptor.

The expression levels of the p202 protein are inversely correlated with the Aim2 and Fc γ RIIB receptor levels

Aim2 deficiency increases the expression of IFN- β , activates IFN signaling, and increases levels of the IFN-inducible p202 protein (42). Given that increased expression of the IFN- β in the B6.*Nba2-ABC* mice is inversely correlated with the Fc γ RIIB receptor levels (Fig. 5), we explored whether the increased levels of the p202 protein could negatively regulate the expression of the Aim2 and *Fcgr2b* genes. For this purpose, we chose to overexpress p202 protein in murine macrophage cell line RAW264.7. We chose these cells because they lack the expression of an adaptor protein ASC (24), thus, allowing stable transfection of an expression plasmid and expression of a transgene. As shown in Fig. 6A, increased expression of the p202 mRNA in RAW264.7 cells was associated with significantly reduced steady-state levels of Aim2 mRNA, increased levels of IFN- β mRNA, and reduced levels of Fc γ RIIB mRNA (these cells express both the B1 and B2 isoforms of the Fc γ RIIB mRNA). Accordingly, increased levels of the p202 protein in RAW264.7 cells significantly decreased basal levels of the Aim2 protein, increased the activating phosphorylation of STAT1 and levels of STAT1 protein, and reduced Fc γ RIIB receptor levels (Fig. 6B). Moreover, consistent with these observations, the knockdown of p202 expression in the murine J774.A1 cell line increased (~2.6-fold) steady-state levels of Fc γ RIIB

protein (Fig. 6C). Collectively, these observations, which are consistent with our previous observations that the Aim2 deficiency stimulates the expression of the *Irf102* gene (42), demonstrate that the expression levels of the p202 protein in immune cells are inversely correlated with the expression levels of the Aim2 and Fc γ RIIB proteins (Fig. 7).

Discussion

Our previous studies (and studies by others) indicated a role for the IFN-inducible p202 protein in lupus susceptibility (8, 20, 22). Furthermore, the generation of subcongenic lines (the B6.*Nba2-A*, B6.*Nba2-B*, and B6.*Nba2-C*) and their comparisons with the control mice (B6 and B6.*Nba2-ABC* mice) revealed that the p202 family proteins may negatively regulate the expression of the *Fcgr2b* gene (13). Because our recent study revealed that the Aim2 deficiency in mice activates the IFN responses and stimulates the expression of the p202 protein (42), we investigated whether the Aim2 deficiency in mice could regulate the expression of the inhibitory receptor Fc γ RIIB. Our experiments revealed the following: 1) Aim2 deficiency in mice or the knockdown of the Aim2 expression in macrophage cell lines, which stimulates the *Irf102* expression (42) and decreases the *Fcgr2b* expression (Fig. 1); and 2) in lupus-prone mice, reduced expression of the Aim2 gene is associated with activation of a type I IFN response (42) and decreased expression of the Fc γ RIIB receptor (Fig. 5). Collectively, these observations demonstrate that the expression of Aim2 protein is required to maintain the expression of the inhibitory Fc γ RIIB receptor.

A selective blockade of the inhibitory Fc γ RIIB receptor in human DCs and monocytes induces a type I IFN response and increased expression of certain ISGs, including the *IFI16* and *AIM2* (37). Therefore, our observations that *Fcgr2b* deficiency in mice activates a type I IFN response (increased levels of IFN- β and activation of STAT1) are consistent with the above report. Moreover, our observations revealed the following: 1) the activation of IFN signaling in the B6 splenic cells decreases the expression of the *Fcgr2b* gene (Fig. 4); 2) in lupus-susceptible B6.*Nba2-ABC* mice, increased expression of the IFN- β and increased levels of the p202 protein (as compared with the B6 mice) are associated with decreases in the expression *Fcgr2b* (Fig. 5) (42); and 3) overexpression of p202 protein in a murine macrophage cell line decreased levels of the Aim2 protein, activated STAT1, and reduced the Fc γ RIIB receptor levels (Fig. 6). Collectively, these observations are consistent with the idea that increased levels of the IFN-inducible p202 protein in certain strains of




FIGURE 6. The expression levels of the p202 protein are inversely correlated with Fc γ RIIB receptor. *A*, Total RNA prepared from RAW264.7 cells either stably transfected with a control vector (pCMV; indicated as V) or a plasmid (pCMV-202; indicated as p202) that allowed the expression of the *Irf102* gene was analyzed by semiquantitative PCR using a pair of primers specific to the indicated genes. *B*, Total cell extracts from RAW264.7 cell clones described in *A* were analyzed by immunoblotting using Abs specific to the indicated proteins. *C*, Total cell extracts from J774.A1 cells infected with control lentivirus (*lane 1*) or sh*Irf102* lentivirus (*lane 2*) were subjected to immunoblotting for the indicated proteins.




FIGURE 7. Proposed regulatory role of the Aim2 protein in the maintenance of the Fc γ RIIB receptor expression through downregulation of the p202 protein expression.

female mice contribute to lupus susceptibility in part by negatively regulating the expression of the *Aim2* and *Fcgr2b* genes.

The expression of p202 protein is gender dependent: higher in the females than in the age-matched males (43). Therefore, our observation that increased levels of p202 protein in *Aim2*-deficient cells are associated with reduced levels of Fc γ RIIB levels raises the possibility that the expression of the *Fcgr2b* gene is also regulated by the gender-dependent factors. In this regard, a study noted higher steady-state levels of the *Fcgr2b* mRNA in 4-mo-old pre-lupus (NZB \times NZW)F₁ males than in females (45). In addition, it has been reported that healthy women had overall lower Fc γ RIIB expression on B cells than men (46). Given that the expression levels of the inhibitory Fc γ RIIB receptor contribute to the regulation of survival and functions of the immune cells (31, 32), including the B cells, it is likely that the gender and mouse strain-dependent decreased levels of the receptor in lupus-prone female mice (e.g., NZB and B6.*Nba2*-ABC) as compared with the B6 mice affect the subpopulations of the immune cells that express the Fc γ RIIB receptor. Therefore, further work will be needed to determine whether the observed differences in the levels of the Fc γ RIIB receptor between various strains of male and the age-matched female mice are associated with increases (or decreases) in certain subpopulations of the immune cells.

Polymorphisms in the promoter region of the *FCGR2B* gene reduce the expression of the receptor in SLE patients (47) and in certain strains of mice (38, 39). As compared with normal healthy B6 mice, autoimmune-prone NZB and MRL mice share three deletions: two in the promoter region and one in the third intronic region (39). Importantly, these polymorphisms correlate well with the extent of downregulation of the *Fcgr2b* expression in germinal center B cells (39). Notably, very low-level expression of an Fc γ RIIB receptor on macrophages expressing the NZB-type *Fcgr2b* allele, as compared with those expressing the B6-type allele, is associated with the development of monocytosis (an indicator for severe SLE disease in mice) in the Fc γ RIIB haploinsufficient B6 mice carrying the *Yaa* mutation (48). Consistent with these observations, we have noted lower levels of Fc γ RIIB receptor expression in purified plasma cells and germinal center B cells from 4-mo-old B6.*Nba2* female mice, which express the NZB-type *Fcgr2b* allele, than the age-matched B6 mice (13). In the current study, we provide evidence that at least two mechanisms contribute to reduced steady-state levels of the Fc γ RIIB receptor in the B6.*Nba2*-ABC mice (as compared with age- and gender-matched B6 mice): 1) polymorphisms involving deletions in the NZB allele (the NZB genotype); and 2) the *Aim2* deficiency, which activates type I IFN responses and induces the expression of the p202 protein (42), which suppresses the expression of the *Fcgr2b* gene (Fig. 5).

The regulation of the expression of the human and murine Fc γ RIIB receptor gene is complex and depends on the cell type (32). Interestingly, the transcription of the human *FCGR2B* gene is activated by the c-Jun/AP-1 transcription factor (49). Moreover, the expression of the murine *Fcgr2b* gene is negatively regulated by IFN- γ (44). Given that the transcription of the human *FCGR2B* gene is activated by the c-Jun/AP-1 transcription factor (49), we have analyzed the 5'-regulatory region (nucleotides from -729 to +585) (44) of the mouse *Fcgr2b* gene for the presence of potential c-Jun/AP-1 DNA binding sites. The search revealed that the regulatory region contains at least two perfect (tgag/ctca) potential c-Jun/AP-1 DNA binding sites. Because increased levels of the p202 protein in cell lines inhibit c-Jun/AP-1-stimulated transcription (50) and increased levels of p202 protein in B6.*Nba2* splenic cells are associated with reduced steady-state levels of c-Jun mRNA (a transcriptional target of the AP-1) after stimulation of B cells

(with anti-IgM for 20 h) as compared with B6 cells (data not shown), it is likely that p202 protein downregulates the expression of the *Fcgr2b* gene in part by inhibiting the c-Jun/AP-1-mediated transcription. Further work will be needed to test this interesting possibility.

Presently, it is not known whether polymorphisms in the promoter region of the *Aim2* gene (or other mechanisms) contribute to its differential expression between non-lupus-prone and lupus-prone strains of mice. Moreover, a comparison of the *Aim2* protein levels in splenic B (B220⁺), T (CD3⁺), and BMDMs (CD11b⁺) from B6 female mice (age, ~8 wk) indicated that the levels of *Aim2* protein are higher in the B cells than in T cells or BMDMs (B > T > BMDM; data not shown). Therefore, although the expression of the *Aim2* protein is detectable in both lymphoid and myeloid cells, it remains to be determined whether the *Aim2* protein-mediated regulation of the *Fcgr2b* gene is cell-type dependent.

Cross-linking of the Fc γ RIIB receptor induces apoptosis of plasma cells (51). Therefore, reduced expression of the inhibitory receptor is predicted to increase cell survival and the production of Abs. Consistent with the above prediction, plasma cells from lupus-prone mice express reduced levels of the Fc γ RIIB receptor and are protected from apoptosis (51). Therefore, our observations that the *Aim2* deficiency results in reduced levels of the Fc γ RIIB receptor in immune cells support the possibility that defects in the expression of the *Aim2* gene are likely to contribute to increased survival of plasma cells that produce the pathogenic autoantibodies. Further work is in progress to test this possibility.

Mice deficient in Fc γ RIIB receptor expression develop anti-nuclear Abs and glomerulonephritis (34–36). Interestingly, DCs from these mice that develop lupus-like disease exhibit altered NF- κ B expression (compared with wild-type mice): reduced expression of the inhibitory protein I κ B α (which indicates the activation of NF- κ B) (52). Moreover, pharmacological inhibition of the activity of NF- κ B in Fc γ RIIB-deficient mice reduces the susceptibility to develop SLE and prevents the symptoms (production of anti-nuclear Abs and glomerulonephritis) (52). Given that increased expression of p202 protein in bone marrow-derived DCs from (NZB \times NZW)F₁ mice stimulates the activity of NF- κ B (53), our observations that overexpression of p202 in RAW264.7 cells decreases levels of Fc γ RIIB receptor (Fig. 5) make it likely that the p202-mediated decrease in the expression of Fc γ RIIB receptor in certain strains of mice contribute to the activation of the transcriptional activity of NF- κ B in DCs. Consistent with this prediction, we have noted reduced expression of I κ B α in splenic cells from the B6.*Nba2* female mice as compared with age-matched B6 mice (data not shown).

A recent study noted that type I IFN signaling inhibits IL-1 (both IL- α and IL- β) production and inflammasome activation (54). Therefore, our observation that the *Aim2* deficiency activates type I IFN response and the expression of IFN-inducible genes are consistent with the idea that the *Aim2* protein and the activation of type I IFN responses are part of a regulatory negative feedback mechanism. Consequently, further work will be needed to understand how defects in the expression of *Aim2* gene contribute to increased production of type I IFNs and associated autoimmune diseases, including lupus.

In summary, our observations support our model (Fig. 7), which predicts that the expression levels of the *Aim2* protein above certain thresholds are required to maintain the expression of the *Fcgr2b* gene in immune cells. Given that the *Aim2* and p202 proteins are part of a mutually negative feedback loop (42), it is conceivable that the mouse-strain and gender-dependent increases in the levels of p202 protein in immune cells reduce the *Aim2*

expression below the threshold, resulting in autostimulation of the *Iff202* expression and suppression of the *Fcgr2b* gene expression. Our observations will serve basis to understand the role of the human AIM2 protein in lupus susceptibility.

Acknowledgments

We thank Dr. J.E. Gessner for generously providing the Fc γ RIIB p(-729/+585)-Luc reporter plasmid.

Disclosures

The authors have no financial conflicts of interest.

References

- Graham, R. R., G. Hom, W. Ortmann, and T. W. Behrens. 2009. Review of recent genome-wide association scans in lupus. *J. Intern. Med.* 265: 680–688.
- Moser, K. L., J. A. Kelly, C. J. Lessard, and J. B. Harley. 2009. Recent insights into the genetic basis of systemic lupus erythematosus. *Genes Immun.* 10: 373–379.
- Kono, D. H., and A. N. Theofilopoulos. 2006. Genetics of SLE in mice. *Springer Semin. Immunopathol.* 28: 83–96.
- Morel, L. 2010. Genetics of SLE: evidence from mouse models. *Nat. Rev. Rheumatol.* 6: 348–357.
- Cohen-Solal, J. F., V. Jeganathan, C. M. Grimaldi, E. Peeva, and B. Diamond. 2006. Sex hormones and SLE: influencing the fate of autoreactive B cells. *Curr. Top. Microbiol. Immunol.* 305: 67–88.
- Crispín, J. C., S. N. Liossis, K. Kis-Toth, L. A. Lieberman, V. C. Kyttaris, Y. T. Juang, and G. C. Tsokos. 2010. Pathogenesis of human systemic lupus erythematosus: recent advances. *Trends Mol. Med.* 16: 47–57.
- Vyse, T. J., S. J. Rozzo, C. G. Drake, S. Izui, and B. L. Kotzin. 1997. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. *J. Immunol.* 158: 5566–5574.
- Rozzo, S. J., J. D. Allard, D. Choubey, T. J. Vyse, S. Izui, G. Peltz, and B. L. Kotzin. 2001. Evidence for an interferon-inducible gene, *Iff202*, in the susceptibility to systemic lupus. *Immunity* 15: 435–443.
- Wither, J. E., A. D. Paterson, and B. Vukusic. 2000. Genetic dissection of B cell traits in New Zealand black mice: the expanded population of B cells expressing up-regulated costimulatory molecules shows linkage to *Nba2*. *Eur. J. Immunol.* 30: 356–365.
- Xiu, Y., K. Nakamura, M. Abe, N. Li, X. S. Wen, Y. Jiang, D. Zhang, H. Tsurui, S. Matsuoka, Y. Hamano, et al. 2002. Transcriptional regulation of *Fcgr2b* gene by polymorphic promoter region and its contribution to humoral immune responses. *J. Immunol.* 169: 4340–4346.
- Wither, J. E., G. Lajoie, S. Heinrichs, Y. C. Cai, N. Chang, A. Ciofani, Y. H. Cheung, and R. MacLeod. 2003. Functional dissection of lupus susceptibility loci on the New Zealand black mouse chromosome 1: evidence for independent genetic loci affecting T and B cell activation. *J. Immunol.* 171: 1697–1706.
- Wandstrat, A. E., C. Nguyen, N. Limaye, A. Y. Chan, S. Subramanian, X. H. Tian, Y. S. Yim, A. Pertsemliadis, H. R. Garner, Jr., L. Morel, and E. K. Wakeland. 2004. Association of extensive polymorphisms in the *SLAMF7* gene cluster with murine lupus. *Immunity* 21: 769–780.
- Jørgensen, T. N., J. Alfaro, H. L. Enriquez, C. Jiang, W. M. Loo, S. Atencio, M. R. Bupp, C. M. Mailloux, T. Metzger, S. Flannery, et al. 2010. Development of murine lupus involves the combined genetic contribution of the *SLAMF7* and *FcγR* intervals within the *Nba2* autoimmune susceptibility locus. *J. Immunol.* 184: 775–786.
- Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 1998. How cells respond to interferons. *Annu. Rev. Biochem.* 67: 227–264.
- Theofilopoulos, A. N., R. Baccala, B. Beutler, and D. H. Kono. 2005. Type I interferons (α/β) in immunity and autoimmunity. *Annu. Rev. Immunol.* 23: 307–336.
- Sen, G. C., and P. Lengyel. 1992. The interferon system. A bird's eye view of its biochemistry. *J. Biol. Chem.* 267: 5017–5020.
- Crow, M. K. 2007. Type I interferon in systemic lupus erythematosus. *Curr. Top. Microbiol. Immunol.* 316: 359–386.
- Santiago-Raber, M. L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. *J. Exp. Med.* 197: 777–788.
- Jørgensen, T. N., E. Roper, J. M. Thurman, P. Marrack, and B. L. Kotzin. 2007. Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 \times NZW)F₁ mice. *Genes Immun.* 8: 653–662.
- Choubey, D., and B. L. Kotzin. 2002. Interferon-inducible p202 in the susceptibility to systemic lupus. *Front. Biosci.* 7: e252–e262.
- Wang, H., G. Chatterjee, J. J. Meyer, C. J. Liu, N. A. Manjunath, P. Bray-Ward, and P. Lengyel. 1999. Characteristics of three homologous 202 genes (*Iff202a*, *Iff202b*, and *Iff202c*) from the murine interferon-activatable gene 200 cluster. *Genomics* 60: 281–294.
- Choubey, D., and R. Panchanathan. 2008. Interferon-inducible *Iff200*-family genes in systemic lupus erythematosus. *Immunol. Lett.* 119: 32–41.
- Choubey, D., X. Duan, E. Dickerson, L. Ponomareva, R. Panchanathan, H. Shen, and R. Srivastava. 2010. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. *J. Interferon Cytokine Res.* 30: 371–380.
- Roberts, T. L., A. Idris, J. A. Dunn, G. M. Kelly, C. M. Burton, S. Hodgson, L. L. Hardy, V. Garceau, M. J. Sweet, I. L. Ross, et al. 2009. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. *Science* 323: 1057–1060.
- Unterholzner, L., S. E. Keating, M. Baran, K. A. Horan, S. B. Jensen, S. Sharma, C. M. Sirois, T. Jin, E. Latz, T. S. Xiao, et al. 2010. IFI16 is an innate immune sensor for intracellular DNA. *Nat. Immunol.* 11: 997–1004.
- Rathinam, V. A., Z. Jiang, S. N. Waggoner, S. Sharma, L. E. Cole, L. Waggoner, S. K. Vanaja, B. G. Monks, S. Ganesan, E. Latz, et al. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. *Nat. Immunol.* 11: 395–402.
- Hornung, V., A. Ablasser, M. Charrel-Dennis, F. Bauernfeind, G. Horvath, D. R. Caffrey, E. Latz, and K. A. Fitzgerald. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. *Nature* 458: 514–518.
- Fernandes-Alnemri, T., J. W. Yu, P. Datta, J. Wu, and E. S. Alnemri. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. *Nature* 458: 509–513.
- Schroder, K., D. A. Muruve, and J. Tschopp. 2009. Innate immunity: cytoplasmic DNA sensing by the AIM2 inflammasome. *Curr. Biol.* 19: R262–R265.
- Krieg, A. M. 2010. AIM2 defend against intracellular pathogens. *Nat. Immunol.* 11: 367–369.
- Tarasenko, T., J. A. Dean, and S. Bolland. 2007. Fc γ RIIB as a modulator of autoimmune disease susceptibility. *Autoimmunity* 40: 409–417.
- Nimmerjahn, F., and J. V. Ravetch. 2008. Fc γ receptors as regulators of immune responses. *Nat. Rev. Immunol.* 8: 34–47.
- Smith, K. G., and M. R. Clatworthy. 2010. Fc γ RIIB in autoimmunity and infection: evolutionary and therapeutic implications. *Nat. Rev. Immunol.* 10: 328–343.
- Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in Fc γ RIIB-deficient mice results from strain-specific epistasis. *Immunity* 13: 277–285.
- Bolland, S., Y. S. Yim, K. Tus, E. K. Wakeland, and J. V. Ravetch. 2002. Genetic modifiers of systemic lupus erythematosus in Fc γ RIIB^{-/-} mice. *J. Exp. Med.* 195: 1167–1174.
- McGaha, T. L., M. C. Karlsson, and J. V. Ravetch. 2008. Fc γ RIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. *J. Immunol.* 180: 5670–5679.
- Dhodapkar, K. M., D. Banerjee, J. Connolly, A. Kukreja, E. Matayeva, M. C. Veri, J. V. Ravetch, R. M. Steinman, and M. V. Dhodapkar. 2007. Selective blockade of the inhibitory Fc γ receptor (Fc γ RIIB) in human dendritic cells and monocytes induces a type I interferon response program. *J. Exp. Med.* 204: 1359–1369.
- Jiang, Y., S. Hirose, R. Sanokawa-Akamura, M. Abe, X. Mi, N. Li, Y. Miura, J. Shirai, D. Zhang, Y. Hamano, and T. Shirai. 1999. Genetically determined aberrant down-regulation of Fc γ RIIB1 in murine systemic lupus erythematosus. *Int. Immunol.* 11: 1685–1691.
- Jiang, Y., S. Hirose, M. Abe, R. Sanokawa-Akamura, M. Ohtsuiji, X. Mi, N. Li, Y. Xiu, D. Zhang, J. Shirai, et al. 2000. Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. *Immunogenetics* 51: 429–435.
- Fernandes-Alnemri, T., J. W. Yu, C. Juliana, L. Solorzano, S. Kang, J. Wu, P. Datta, M. McCormick, L. Huang, E. McDermott, et al. 2010. The AIM2 inflammasome is critical for innate immunity to *Francisella tularensis*. *Nat. Immunol.* 11: 385–393.
- Jones, J. W., N. Kayagaki, P. Broz, T. Henry, K. Newton, K. O'Rourke, S. Chan, J. Dong, Y. Qu, M. Roose-Girma, et al. 2010. Absent in melanoma 2 is required for innate immune recognition of *Francisella tularensis*. *Proc. Natl. Acad. Sci. USA* 107: 9771–9776.
- Panchanathan, R., X. Duan, H. Shen, V. A. K. Rathinam, L. D. Erickson, K. A. Fitzgerald, and D. Choubey. 2010. Aim2 deficiency stimulates the expression of IFN-inducible *Iff202*, a lupus susceptibility murine gene within the *Nba2* autoimmune susceptibility locus. *J. Immunol.* 185: 7385–7393.
- Panchanathan, R., H. Shen, M. G. Bupp, K. A. Gould, and D. Choubey. 2009. Female and male sex hormones differentially regulate expression of *Iff202*, an interferon-inducible lupus susceptibility gene within the *Nba2* interval. *J. Immunol.* 183: 7031–7038.
- Konrad, S., L. Engling, R. E. Schmidt, and J. E. Gessner. 2007. Characterization of the murine IgG Fc receptor III and IIB gene promoters: a single two-nucleotide difference determines their inverse responsiveness to C5a. *J. Biol. Chem.* 282: 37906–37912.
- Gubbels Bupp, M. R., T. N. Jørgensen, and B. L. Kotzin. 2008. Identification of candidate genes that influence sex hormone-dependent disease phenotypes in mouse lupus. *Genes Immun.* 9: 47–56.
- Prokopec, K. E., M. Rhodiner, P. Matt, U. Lindqvist, and S. Kleinau. 2010. Down regulation of Fc and complement receptors on B cells in rheumatoid arthritis. *Clin. Immunol.* 137: 322–329.
- Blank, M. C., R. N. Stefanescu, E. Masuda, F. Marti, P. D. King, P. B. Redecha, R. J. Wurzburger, M. G. Peterson, S. Tanaka, and L. Pricop. 2005. Decreased transcription of the human *FCGR2B* gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. *Hum. Genet.* 117: 220–227.
- Kikuchi, S., M. L. Santiago-Raber, H. Amano, E. Amano, L. Fossati-Jimack, T. Moll, B. L. Kotzin, and S. Izui. 2006. Contribution of NZB autoimmunity 2 to

- Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. *J. Immunol.* 176: 3240–3247.
49. Olfertiev, M., E. Masuda, S. Tanaka, M. C. Blank, and L. Pricop. 2007. The role of activating protein 1 in the transcriptional regulation of the human *FCGR2B* promoter mediated by the -343 G→C polymorphism associated with systemic lupus erythematosus. *J. Biol. Chem.* 282: 1738–1746.
50. Min, W., S. Ghosh, and P. Lengyel. 1996. The interferon-inducible p202 protein as a modulator of transcription: inhibition of NF-κB, c-Fos, and c-Jun activities. *Mol. Cell. Biol.* 16: 359–368.
51. Xiang, Z., A. J. Cutler, R. J. Brownlie, K. Fairfax, K. E. Lawlor, E. Severinson, E. U. Walker, R. A. Manz, D. M. Tarlinton, and K. G. C. Smith. 2007. FcγRIIB controls bone marrow plasma cell persistence and apoptosis. *Nat. Immunol.* 8: 419–429.
52. Kalergis, A. M., M. I. Iruretagoyena, M. J. Barrientos, P. A. González, A. A. Herrada, E. D. Leiva, M. A. Gutiérrez, C. A. Riedel, S. M. Bueno, and S. H. Jacobelli. 2009. Modulation of nuclear factor-κB activity can influence the susceptibility to systemic lupus erythematosus. *Immunology* 128(Suppl. 1): e306–e314.
53. Yamauchi, M., M. Hashimoto, K. Ichiyama, R. Yoshida, T. Hanada, T. Muta, S. Komune, T. Kobayashi, and A. Yoshimura. 2007. *Ifi202*, an IFN-inducible candidate gene for lupus susceptibility in NZB/W F₁ mice, is a positive regulator for NF-κB activation in dendritic cells. *Int. Immunol.* 19: 935–942.
54. Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Förster, M. Farlik, T. Decker, R. A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. *Immunity* 34: 213–223.